High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T. Bate-Eya, M. Emmy M. Dolman|Oncotarget|2016Cited by 61
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma CellsLindy Vernooij, M. Emmy M. Dolman|Molecular Cancer Therapeutics|2021Cited by 18